Amylyx Pharmaceuticals Advances Avexitide in Phase 3 Trial
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) recently unveiled its design for the pivotal Phase 3 LUCIDITY clinical trial for avexitide, a groundbreaking glucagon-like peptide-1 (GLP-1) receptor antagonist. This trial aims to address the treatment of post-bariatric hypoglycemia (PBH), a condition affecting numerous patients after bariatric surgery. The trial’s primary focus is to evaluate the efficacy of avexitide in reducing the frequency of hypoglycemic events, as agreed upon by the FDA. With expectations to dose the first participant in early 2025 and to finalize recruitment within the same year, topline data is anticipated in 2026.
Significance of the Phase 3 LUCIDITY Trial
In an effort to provide effective solutions for patients, the LUCIDITY trial will adopt similar inclusion and exclusion criteria established in previous Phase 2 trials of avexitide. "We are excited to advance avexitide into a Phase 3 clinical trial, marking a pivotal step toward bringing this investigational therapy to people living with PBH,” expressed Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. This enthusiastic outlook extends from the consistent and encouraging data gathered from five clinical trials involving avexitide.
Details of the LUCIDITY Trial
This upcoming trial is designed as a multicenter, randomized, double-blind, placebo-controlled investigation. It will include approximately 75 participants who have undergone Roux-en-Y gastric bypass (RYGB) surgery. The participants will be randomly assigned to receive either 90 mg of avexitide, administered subcutaneously once daily, or a placebo. Each participant will undergo a three-week run-in period, followed by a 16-week double-blind treatment phase, with those completing this stage allowed to enter an open-label extension period lasting 32 weeks.
Understanding Post-Bariatric Hypoglycemia
Post-bariatric hypoglycemia (PBH) is a condition that arises primarily due to an excessive GLP-1 response, leading to repeated, debilitating episodes of hypoglycemia. Such instances not only disrupt daily life but can also severely impact cognitive function and overall well-being.
How Avexitide Works
The mechanism of action for avexitide involves binding to GLP-1 receptors, effectively inhibiting the excessive activity that leads to hypoglycemia. The objective is to stabilize blood glucose levels by minimizing insulin secretion. Various studies have highlighted the significant beneficial effects of avexitide on reducing the frequency of hypoglycemic episodes among users, showcasing the drug’s potential as a transformative treatment.
Clinical Trials Supporting Avexitide
The development of LUCIDITY is supported by robust data drawn from five important clinical trials evaluating the efficacy of avexitide for PBH. For instance, one notable Phase 2 trial displayed a significant reduction in rates of Level 2 and Level 3 hypoglycemia among participants, showcasing the compound's promise in providing relief for those affected.
In addition, in the Phase 2b trial, participants experienced a 53% and 66% reduction in Level 2 and Level 3 hypoglycemic events, respectively. Such compelling outcomes reinforce Amylyx’s confidence in the efficacy of avexitide.
Amylyx’s Commitment to Innovation
Amylyx aims to continue its collaborative efforts with study investigators and the PBH community, with a strong commitment to advancing avexitide through the clinical development process. Dr. Camille L. Bedrosian, Chief Medical Officer, is optimistic about this research path, stating, “We believe LUCIDITY is well powered to detect a treatment effect...”.
About Amylyx Pharmaceuticals
With a focus on high unmet needs in the medical community, Amylyx Pharmaceuticals is dedicated to innovating treatment options for serious neurodegenerative diseases and endocrine disorders. Headquartered in Cambridge, Massachusetts, the company takes pride in a science-driven approach, centering its research endeavors around patient needs.
Frequently Asked Questions
1. What is the purpose of the Phase 3 LUCIDITY trial?
The LUCIDITY trial aims to evaluate the efficacy and safety of avexitide in reducing hypoglycemic events in patients suffering from post-bariatric hypoglycemia.
2. Who is eligible to participate in the trial?
Participants must have undergone Roux-en-Y gastric bypass surgery and meet specific inclusion and exclusion criteria established for the study.
3. When is the trial expected to start?
The first participant is expected to be dosed in early 2025, with recruitment completion anticipated within that same year.
4. What are the anticipated outcomes of the trial?
The primary outcome is the reduction of Level 2 and Level 3 hypoglycemia events, with data expected to be available in 2026.
5. How does avexitide help patients with PBH?
Avexitide works by inhibiting excessive GLP-1 functions that lead to hypoglycemia, ultimately helping to stabilize blood glucose levels and improve patients' quality of life.
